Next-Generation Point-of-Care Tests for Longitudinal Monitoring of Patients Treated for Human Papilloma Virus (HPV)-Driven Cancer

点击翻译按钮获取中文摘要

Circulating human papilloma virus DNA (cHPV-DNA) has shown great promise as a biomarker of residual disease and for disease surveillance following radical treatment for HPV related cancers. For example in feasibility studies at The Royal Marsden Hospital, next generation sequencing assays have been performed for measuring cHPV-DNA that included patients with head and neck, cervical and anal squamous cell carcinoma. However, this assay is resource intense, in terms of personnel, cost and time required. In the proposed project we will develop a rapid, cost-effective assay to measure cHPV-DNA in plasma, and will ultimately enable the development of next-generation HPV-selective point-of-care tests.